IT.12 (YUL) - Male Hypogonadism

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 23

Male Hypogonadism and

Testosteron Therapy
• Male hypogonadism
- The body doesn't produce enough
testosterone — the hormone that plays
a key role in masculine growth and
development during puberty — or has
an impaired ability to produce sperm or
both
Development of the male reproductive
system
- Male sexual development starts between the 7th and 12th
week of gestation

- The undifferentiated gonads develop into a fetal testis


through expression of the sex-determining region Y gene
(SRY), a gene complex located on the short arm of the
Y chromosome

- The fetal testis produces two hormones: testosterone


and anti-Müllerian hormone (AMH)
Development of the male reproductive
system
Testosterone is needed for the development of the Wolffian ducts,
resulting in formation of the epididymis, vas deferens and
seminal vesicle

AMH activity results in regression of the Müllerian ducts

Under the influence of intratesticular testosterone, the number of


gonocytes per tubule increases threefold during the fetal period
Development of the male reproductive
system
Testosterone is needed for development of the prostate, penis and
scrotum

However, in these organs testosterone is converted into the more


potent metabolite dehydrotestosterone (DHT) by the enzyme 5a-
reductase

The enzyme is absent in the testes, which explains why 5a-


reductase inhibitors do not have a marked effect on
spermatogenesis
Development of the male reproductive
system
Intratesticular testosterone is needed to maintain the spermatogenic process
and to inhibit germ cell apoptosis

The seminiferous tubules of the testes are exposed to concentrations of


testosterone 25-100 times greater than circulating levels

Suppression of gonadotrophins (e.g. through excessive testosterone


abuse) results in a reduced number of spermatozoa in the ejaculate
and hypospermatogenesis

Complete inhibition of intratesticular testosterone results in full cessation of


meiosis up to the level of spermatids
Hypogonadism

Hypogonadism is defined as “inadequate gonadal


function, as manifested by deficiencies in gametogenesis
and/or the secretion of gonadal hormones”

These abnormalities usually result from disease of the


testes (primary hypogonadism) or disease of the pituitary
or hypothalamus (secondary hypogonadism)

In occasional cases, a defect in the ability to respond to


testosterone is the cause of hypogonadism
Hypergonadotropic Hypogonadism

Patients with hypergonadotropic hypogonadism may


have some or all of the following characteristic findings:
• Increased FSH level
• Increased LH level
• Low testosterone level
• Impaired production of sperm
Hypogonadotropic Hypogonadism

The condition of hypogonadotropic hypogonadism is


generally associated with the following findings:
• Low or low-normal FSH level
• Low or low-normal LH level
• Low testosterone level
• Impaired production of sperm
Primary and Secondary Hypogonadism

Primary hypogonadism differs from secondary hypogonadism in


two ways:

 Primary hypogonadism is more likely to be associated with a


decrease in sperm production than in testosterone production

 As a consequence, the sperm count may be low, and the


serum FSH concentration normal or high, yet the serum
testosterone concentration remains normal
In contrast, in secondary hypogonadism, there is a
proportionate
reduction in testosterone and sperm production
Primary hypogonadism differs from secondary
hypogonadism in two ways:

 Primary hypogonadism is more likely to be associated


with gynecomastia, presumably due to the stimulatory
effect of the supranormal serum FSH and LH
concentrations on testicular aromatase activity. This
results in increased conversion of testosterone to
estradiol
General Manifestations

Symptoms of hypogonadism depend primarily on the age of the male patient


at the time of development of the condition.

AACE Hypogonadism Guidelines, Endocr Pract. 2002;8(No. 6)


General Manifestations

Symptoms of hypogonadism depend primarily on the age of the male


patient at the time of development of the condition

When hypogonadism develops before the age of puberty, the


manifestations are those of impaired puberty:
• Small testes, phallus, and prostate
• Scant pubic and axillary hair
• Disproportionately long arms and legs (from delayed epiphyseal
closure)
• Reduced male musculature
• Gynecomastia
• Persistently high-pitched voice
General Manifestations

In men in whom androgen deficiency develops after completion of


pubertal maturation, symptoms of androgen deficiency include:
 reduced sexual desire and activity,
 decreased spontaneous erections,
 loss of body hair and reduced frequency of shaving,
 infertility,
 reduced muscle bulk and strength,
 hot flushes and sweats,
height loss due to atraumatic fracture,
 small or shrinking testes,
 breast enlargement or tenderness
Less-specific symptoms include decreased energy, motivation, and
initiative; sad or blue feelings, depressed mood, dysthymia; poor
concentration and memory; sleep disturbance and increased
sleepiness; increased body fat; and diminished physical or work
capacity.
Testosterone therapy
 Testosterone therapy for symptomatic men with classical androgen
deficiency syndromes

 Aimed at inducing and maintaining secondary sex characteristics and at


improving their sexual function, sense of well-being, and bone mineral
density

 The therapeutic target should be to raise serum


testosterone levels into a range that is mid-normal for
healthy, young men
Testosterone therapy in men with sexual
dysfunction

Testosterone therapy to men with low testosterone levels and


low libido to improve libido and to men with ED who have
low testosterone levels after evaluation of underlying causes
of ED and consideration of established therapies for ED
HIV-infected men with weight loss

We suggest that clinicians consider short-term testosterone


therapy as an adjunctive therapy in HIV-infected men with low
testosterone levels and weight loss to promote weight
maintenance and gains in LBM and muscle strength.

Guidelines for Testosterone Therapy in Androgen-Deficient Men J Clin Endocrinol Metab, June 2010,
95(6):2536–2559
Glucocorticoid-treated men

We suggest that clinicians offer testosterone therapy to


men receiving high doses of glucocorticoids who have low
testosterone levels to promote preservation of LBM and bone
mineral density.

Guidelines for Testosterone Therapy in Androgen-Deficient Men J Clin Endocrinol Metab, June 2010,
95(6):2536–2559
Time course of effects

The time course of the effects of testosterone


replacement is variable.

Increases in fat-free mass, prostate volume,


erythropoiesis, energy, and sexual function occurred
within the first three to six months.

In contrast, the full effect on bone mineral density


(BMD) did not occur until 24 months.
Benefit of TRT

In general, the benefits of TRT are more consistent in men


with very low testosterone concentrations than in those
with concentrations just below the normal range.

Health care professionals should make patients aware of


the possible increased cardiovascular risk when deciding
whether to start or continue a patient on testosterone therapy.

TRT should not be provided to men who have untreated or


metastatic prostate cancer or breast cancer.
Testosterone and Cardiovascular Risk, Endocr Prac. 2015;21(No. 9)
Relative contra-indications include :
untreated severe sleep apnea,
a hematocrit >50%,
severe lower urinary tract symptoms with an International Prostate
Symptom Score above 19,
uncontrolled or poorly controlled heart failure,
 a MI or cerebrovascular accident within the past 6 months,
a personal or family history of a procoagulant state,
or a personal history of thromboembolism

Testosterone and Cardiovascular Risk, Endocr Prac. 2015;21(No. 9)


Thank You

You might also like